13F-HR filed by Trails Edge Capital Partners, LP
Trails Edge Capital Partners, LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 23 holding rows worth $404,736,054.
- Accession
- 0002077247-26-000002
- Filer
- CIK 2077247
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 23 entries on the cover page, a total value of $404,736,054 stated on the cover page (in dollars after the unit check, H1), rows summing to $404,736,054 with VALUE read as dollars as filed, 13F file number 028-26566. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ACADIA PHARMACEUTICALS INC | 004225108 | COM | 1,419,406 | $37,912,334 | dollars as filed | |
| MIND MEDICINE MINDMED INC | 60255C885 | COM NEW | 2,568,110 | $34,386,993 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 737,470 | $34,026,866 | dollars as filed | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 1,743,220 | $33,068,884 | dollars as filed | |
| LB PHARMACEUTICALS INC | 50180M108 | COMMON STOCK | 1,395,608 | $31,066,234 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 597,092 | $26,761,664 | dollars as filed | |
| IMMUNOCORE HLDGS PLC ADS | 45258D105 | ADR | 682,597 | $23,692,942 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 916,313 | $21,835,738 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 700,000 | $18,403,000 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 785,000 | $16,171,000 | dollars as filed | |
| AMICUS THERAPEUTICS INC | 03152W109 | COM | 1,043,313 | $14,856,777 | dollars as filed | |
| APOGEE THERAPEUTICS INC COM | 03770N101 | Stock | 192,000 | $14,492,160 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 6,178,124 | $12,665,154 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 2,657,997 | $12,359,686 | dollars as filed | |
| CAMP4 THERAPEUTICS CORP | 13463J101 | COM | 1,983,986 | $12,161,834 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 300,000 | $12,120,000 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 2,571,478 | $10,285,912 | dollars as filed | |
| MBX BIOSCIENCES INC COM | 55287L101 | Stock | 315,158 | $9,940,084 | dollars as filed | |
| VTV THERAPEUTICS INC | 918385204 | CL A NEW | 231,000 | $9,237,690 | dollars as filed | |
| COMPASS THERAPEUTICS INC | 20454B104 | COM | 1,415,273 | $7,600,016 | dollars as filed | |
| IMMUNOVANT INC | 45258J102 | COM | 240,165 | $6,104,994 | dollars as filed | |
| ENLIVEN THERAPEUTICS INC COM | 29337E102 | Stock | 199,306 | $3,069,312 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 31,862 | $2,516,780 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002077247-26-000002 | this filing | 2026-02-17 | acceptance time not in the bulk data set |